REGENXBIO Inc. (RGNX) SEC Filings

REGENXBIO Inc. (RGNX) reported that Chief Financial Officer Mitchell Chan had 4,902 shares of common stock withheld on September 1, 2026 to pay tax liabilities arising from the vesting of restricted stock units originally granted on September 16, 2024. The shares were valued at $9.32 per share, based on the issuer’s closing price that day, and reflect a tax-withholding disposition rather than an open-market sale. Following this event, Chan directly holds 122,815 shares of REGENXBIO common stock. No Rule 10b5-1 trading plan is reported for this transaction.

REGENXBIO Inc. (RGNX) director Gregory Austin Ciongoli reported multiple equity transactions. He purchased 49,196 shares of common stock on August 26, 2026 at a weighted average price of $9.1411 per share in open-market trades, and 53,407 shares on August 27, 2026 at a weighted average price of $9.3560 per share in open-market trades.

On August 25, 2026, he also received an equity compensation package consisting of 15,432 shares of time-based restricted stock units that vest in three equal annual installments on August 25, 2027, 2028 and 2029, and a stock option for 69,609 shares of common stock at an exercise price of $8.91 per share, vesting one-third on August 25, 2027 and the remainder in equal monthly installments over the following 24 months.

REGENXBIO Inc. (RGNX) filed an initial insider ownership report (Form 3) for Gregory Austin Ciongoli, who is identified as a director of the company. The filing does not list any equity transactions or current holdings and includes a Power of Attorney as an exhibit.

REGENXBIO Inc. (RGNX) reported board and leadership changes along with related director compensation. The board elected Gregory (Greg) Ciongoli as an independent Class II director effective August 25, 2026, with his term running until the 2029 annual meeting. He was also appointed to the Audit Committee and the Nominating and Corporate Governance Committee.

Under the non-employee director compensation program, Mr. Ciongoli received an initial equity award with a grant date fair value of $550,000, split 75% into stock options and 25% into RSUs, with an exercise price of $8.91 per share and three-year vesting schedules, including full acceleration upon a change of control or death. He will receive a $45,000 annual board retainer plus $10,000 and $5,000 retainers for Audit and Nominating and Corporate Governance Committee service, respectively, and will be eligible for future annual equity awards.

The board accepted the resignations of directors Jean Bennett, M.D., Ph.D. and A.N. “Jerry” Karabelas, Ph.D., effective August 25, 2026. Both will serve as advisors to the company through February 2027, and the board size was reduced to nine directors.

REGENXBIO Inc. (RGNX) reported a significant regulatory setback for its RGX-121 gene therapy program for Mucopolysaccharidosis type II (Hunter Syndrome). The FDA has placed the Investigational New Drug application for the Phase I/II/III trial of RGX-121 on a clinical hold, and the company does not expect to resubmit the RGX-121 Biologics License Application in the near term.

The hold follows discovery of asymptomatic spine MRI findings (small nodules or cystic masses) in five CAMPSIITE® study participants dosed approximately three to six years ago. Investigators deemed these findings nonserious and radiologists believe they are likely benign, with patients showing stability to improvement on neurocognitive and neurobehavioral assessments. REGENXBIO states it remains focused on other late-stage programs, including RGX-202 for Duchenne muscular dystrophy and ABBV‑RGX‑314 for wet AMD and diabetic retinopathy, with upcoming regulatory and data milestones described as on track.

REGENXBIO Inc. reported second-quarter 2026 results with total revenues of $108.0 million, up from $21.4 million a year earlier, largely driven by a $100.0 million milestone payment from AbbVie tied to the Phase IIb/III NAAVIGATE diabetic retinopathy study. The company generated net income of $22.7 million, or $0.43 per share, compared with a $70.9 million net loss in Q2 2025. R&D expenses were $56.1 million and G&A expenses were $21.6 million. Cash, cash equivalents and marketable securities were $105.5 million at June 30, 2026; including July milestone and equity offering proceeds, pro forma cash was approximately $313 million, which the company expects will fund operations into Q4 2027.

Clinically, the Phase III AFFINITY DUCHENNE trial of RGX-202 for Duchenne muscular dystrophy met its primary endpoint with high statistical significance, with RGX-202 well-tolerated and commercial supply being produced in-house. The company plans to initiate a RGX-202 BLA submission in Q3 2026 under the accelerated approval pathway, with potential approval in 2H 2027 and an ex-U.S. AFFINITY RISE trial starting in 1H 2027. In retinal disease, long-term data for sura-vec (ABBV-RGX-314) support durable safety and efficacy, with pivotal wet AMD readouts from ATMOSPHERE and ASCENT expected in Q4 2026 and the NAAVIGATE Phase IIb/III DR study underway. For NAVSUNLI (RGX-121) in Hunter syndrome, a positive FDA Type A meeting confirmed no additional studies are required for BLA resubmission, which is planned for Q3 2026.

REGENXBIO Inc. Chief Medical Officer Steve Pakola reported a tax-withholding disposition of 7,468 shares of common stock on August 1, 2026, at $9.69 per share. The shares were withheld to cover taxes on vesting restricted stock units granted August 1, 2024. He now directly holds 205,541 shares.

REGENXBIO Inc. executive Patrick J. Christmas, Chief Strategy & Legal Officer, reported a tax-withholding disposition of 4,699 shares of common stock on August 1, 2026 at $9.69 per share. The shares were withheld to cover taxes on vesting RSUs granted August 1, 2024, leaving him with 205,968 shares held directly. The transaction was not made under a Rule 10b5-1 trading plan.